AMENDMENTS TO THE CLAIMS

Claim 1 (Currently Amended) A pharmaceutical composition which can be administered orally, containing efletirizine as active principle, ~~characterized in that~~ wherein it combines at least one fraction which allows the immediate release of the efletirizine and at least one fraction which allows prolonged release of efletirizine.

Claim 2 (Currently Amended) The composition as claimed in claim 1, ~~characterized in that~~ wherein the total amount of efletirizine in the composition is between 10 and 70 mg, and the weight ratio of the amount of active principle in the immediate-release fraction to the amount of active principle in the prolonged-release fraction is between 3 and 0.025.

Claim 3 (Currently Amended) A pharmaceutical composition which can be administered orally, containing efletirizine as active principle, ~~characterized in that~~ wherein it combines at least one fraction which allows immediate release of the efletirizine and at least one fraction which allows prolonged release of the efletirizine, the respective amounts of active principle in the two fractions being the values included on or between the two straight lines defined by the following equations:

$$Y = -0.6786X + 56.675$$

$$Y = -0.6636X + 7.975$$

in which,

Y represents the amount of efletirizine in milligrams (mg) in the immediate-release fraction, and

X represents the amount of efletirizine in milligrams (mg) in the prolonged-release fraction, and

the total amount X + Y being between 10 and 70 mg.

Claim 4 (Currently Amended) The composition as claimed in claim 3, ~~characterized in that~~ wherein it can be administered in a single daily dose, while obtaining the desired therapeutic effect.

Claim 5 (Currently Amended) The composition as claimed in ~~any one of claims 1 to 4, characterized in that~~ claim 1, wherein the two fractions are provided in the form of a two-layer tablet.

Claim 6 (Currently Amended) The composition as claimed in ~~any one of claims 1 to 5, characterized in that~~ claim 1, wherein the fraction which allows prolonged release of the efletirizine contains less than 5% by weight of basifying agent, weight relative to the total weight of the fraction.